semaglutide glycine cyanocobalamin b12 How to avoid cyanocobalamin in compounded semeglutide injection? microdose compounded semaglutide with glycine

Physicians should avoid prescribing it to: Patients with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). Individuals with severe gastrointestinal conditions, such as gastroparesis. Patients with a known allergy to GLP-1 receptor agonists. Pregnant or breastfeeding women, unless approved by a physician

Semaglutide, a GLP-1 receptor agonist used for type 2 diabetes and weight management, requires careful temperature control to maintain its effectiveness

[DOI] [PubMed] [Google Scholar] 69.Becker C, Lord SR, Studenski SA, et al

Glycemic Control and Type 2 Diabetes Mellitus: The Optimal Hemoglobin A1c Targets

These effects include: Disclosed Side Effects: Inflammation of the pancreas (pancreatitis) Vision changes Kidney failure and other kidney problems Allergic reactions Additional Potential Dangers: Gallstones Acute gallbladder disease (cholecystitis) Thyroid tumors or thyroid cancer Diabetic retinopathy Hypoglycemia (low blood sugar) Gastroparesis (stomach paralysis) It is important for individuals to understand these potential risks and discuss them with a healthcare professional

The Wegovy UK prescribing information has no cancer-related contraindications, and a 2025 SELECT trial analysis found no increase in breast cancer rates on semaglutide compared with placebo